Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Mar 27, 2023; 15(3): 420-429
Published online Mar 27, 2023. doi: 10.4240/wjgs.v15.i3.420
Table 1 Basic information on patients (n = 43)
Variables
Data
Characteristics
Sex (Male/female)34/9
Age (yr), mean ± SD43.6 ± 2.7
Smoking (No/Yes)23/20
Drinking (No/Yes)26/17
Clinical data
Crohn’s disease/ulcerative colitis27/16
Location
Crohn disease (L1/L2/L3/L4)9/0/18/0
Ulcerative colitis (E1/E2/E3)0/2/14
Severity of illness (Mild/moderate/severe)10/21/12
Cause of surgery
Patient required3
Non-response to intern medicine therapy9
Medical required31
Intestinal obstruction18
Fistula5
Definite diagnosis requires1
Gastrointestinal bleeding3
Intestinal stenosis1
Gastrointestinal perforation2
Carcinogenesis1
Pre-op aminosalicylic acid (No/Yes)8/35
Pre-op corticosteroids (No/Yes)24/19
Pre-op immunosuppressive therapy (No/Yes)34/9
Surgical procedures (Laparoscopic/open surgery) 14/29
Course (d), mean ± SD73.6 ± 11.7
Indicators to be explored
Latent Epstein-Barr virus infection (Negative/positive)33/10
Table 2 Vital signs, clinical manifestations and biochemical data of the patients (n = 43)
Variables
Data
Vital signs
Heart rate (time/min), mean ± SD87.2 ± 3.1
Systolic pressure (mmHg), median (Q1, Q3)101.0 (94.5, 113.0)
Diastolic pressure (mmHg), mean ± SD66.2 ± 1.7
Clinical manifestations
Fever (No/Yes)26/17
Abdominal pain (No/Yes)1/42
Diarrhea (No/Yes)14/29
Fecal occult blood (No/Yes)23/20
Mucus or bloody purulent stool (No/Yes)28/15
Lose weight (≥ 5 kg) (No/Yes)4/39
Abdominal mass (No/Yes)29/14
Toxic megacolon (No/Yes)41/2
Gastrointestinal hemorrhage (No/Yes)29/14
Intestinal obstruction (No/Yes)19/24
Intestinal perforation (No/Yes)34/9
Perianal disease (No/Yes)35/8
Extraintestinal manifestations (No/Yes)27/16
Oral ulcer (Yes)13
Pyoderma gangrenosum (Yes)1
Peripheral spondyloarthritis (Yes)6
Others (Yes)2
Biochemical data
White blood cell (× 109/L), mean ± SD6.7 ± 0.6
Neutrophil count (× 109/L), mean ± SD4.6 ± 0.5
Hemoglobin (g/L), mean ± SD103.6 ± 4.5
Platelets (× 109/L), mean ± SD343.2 ± 25.7
Alanine aminotransferase (U/L), median (Q1, Q3)11.0 (8.0, 14.0)
Aspartate aminotransferase (U/L), median (Q1, Q3)14.0 (10.3, 18.8)
Albumin (g/L), mean ± SD30.6 ± 1.5
Lactate dehydrogenase (U/L), median (Q1, Q3)127.0 (102.0, 140.0)
Creatinine (μmol/L), mean ± SD60.7 ± 3.0
Potassium (mmol/L), mean ± SD3.8 ± 0.1
Prothrombin time (s), mean ± SD12.2 ± 0.2
Activated partial thromboplastin time (s), median (Q1, Q3)29.3 (26.5, 32.9)
C-reactive protein (g/L), median (Q1, Q3)26.3 (16.3, 71.4)
Table 3 Summary of factors related to latent Epstein-Barr virus infection
Variables
Epstein-Barr virus-negative (n = 33)
Epstein-Barr virus-positive (n = 10)
Statistical value (t/χ2)
P value
Systolic pressure (mmHg), mean ± SD106.56 ± 11.5194.33 ± 7.712.991 (t)0.0051
Variety of disease7.965 (Adjusted)0.0051
Crohn disease252
Ulcerative colitis88
Severity of illness12.293 (Likelihood ratio)0.0021
Mild82
Moderate201
Severe57
Pre-op corticosteroids5.017 (Adjusted)0.0251
No222
Yes118
Table 4 Data comparison between patients with mild/moderate or severe inflammatory bowel disease
Variables
Mild/moderate (n = 31)
Severe (n = 12)
Statistical value (t/χ2)
P value
Systolic pressure (mmHg), mean ± SD107.33 ± 11.69894.45 ± 7.713.482 (t)0.0011
Variety of disease12.542 (Adjusted)0.0001
Crohn disease252
Ulcerative colitis610
Pre-op corticosteroids6.4080.0111
No213
Yes109
Latent Epstein-Barr virus infection8.911 (Adjusted)0.0031
Negative285
Positive37